ArticleESMO open2026
Real-world effectiveness of molecular-matched therapies in salivary gland cancer.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalivary gland cancer (SGC) is a rare cancer comprising over 20 subtypes. Although its molecular landscape is increasingly characterised, real-world data on molecular-matched therapies (MMTs) remain limited, and predictive biomarkers are needed. PATIENTS AND
methodsSince 2017, real-world data of patients with SGC attending the outpatient clinic at Radboud university medical center have been systematically collected. Best overall response to MMT was assessed per RECIST v1.1. Median progression-free survival (mPFS) was estimated using Kaplan-Meier statistics and compared between the molecular subgroups using the log-rank test.
resultsAt data cutoff, the database contained 662 patients with SGC, including 464 patients with recurrent and/or metastatic disease. Among them, 381 patients exhibited ≥1 molecular alteration, of whom 54% received MMT. Among patients with salivary duct carcinoma (SDC), 83% of patients with ≥1 molecular alteration received MMT, compared with 25% with adenoid cystic carcinoma. In 110 patients with SDC, mPFS with any first-line androgen receptor axis-targeted therapy was 5.3 months [95% confidence interval (CI) 3.5-7.2 months] and was significantly longer in HRAS-mutant (19.1 months; 95% CI 11.0-27.2 months; n = 18) versus HRAS-wild-type cases (3.8 months; 95% CI 2.0-5.6 months; n = 64; P = 0.007). With the first human epidermal growth factor receptor 2-targeted therapy given (n = 35), mPFS was 8.5 months (95% CI 6.4-10.6 months), with objective responses in 61% of RECIST-assessable patients (n = 28). Additionally, objective responses were achieved with other MMTs, including vemurafenib/cobimetinib in BRAF V600E-mutant SDC (n = 3), larotrectinib in secretory carcinoma with ETV6::NTRK3 gene fusions (n = 2), and ipilimumab/nivolumab in mucoepidermoid carcinoma with high tumour mutational burden (n = 1).
conclusionsComprehensive molecular testing in SGC may allow access to MMT, with a subset of patients experiencing clinical benefit from this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.